Response to Comments: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This record (A60223) is an administrative response-to-comments notice for MolDX LCD DL39919 and does not include specific clinical coverage criteria. The notice period for DL39919 begins 2025-07-03 and the LCD becomes effective 2025-08-17; retrieve the full DL39919 LCD to extract actionable indications, limitations, documentation requirements, and frequency limits.

"This document is a response-to-comments notice for MolDX LCD DL39919 and contains only administrative metadata (comment period and effective dates); it does not contain clinical coverage criteria o..."

Sign up to see full coverage criteria, indications, and limitations.